Cytokine-Driven Divergence Between Allogeneic CAR-T Platforms Post author:andrewkaretas Post published:May 13, 2026 Post category:PLATFORM/Scientific Publications Continue ReadingCytokine-Driven Divergence Between Allogeneic CAR-T Platforms
Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma Post author:andrewkaretas Post published:April 20, 2026 Post category:BCMA/Scientific Publications Continue ReadingPreclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma
First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study Post author:andrewkaretas Post published:December 31, 2025 Post category:CD19/Scientific Publications Continue ReadingFirst-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study
ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study Post author:andrewkaretas Post published:June 1, 2025 Post category:CD70/Scientific Publications Continue ReadingALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study
ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy Post author:andrewkaretas Post published:June 1, 2025 Post category:CD19/Scientific Publications Continue ReadingALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy
Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies Post author:andrewkaretas Post published:February 12, 2025 Post category:CD19/Scientific Publications Continue ReadingAllogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies Post author:andrewkaretas Post published:February 12, 2025 Post category:CD19/Scientific Publications Continue ReadingSupplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies
Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy Post author:andrewkaretas Post published:December 9, 2024 Post category:CD19/Scientific Publications Continue ReadingAlpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy
Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases Post author:andrewkaretas Post published:November 18, 2024 Post category:Dual/Scientific Publications Continue ReadingPreclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
ALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study Post author:andrewkaretas Post published:November 7, 2024 Post category:CD70/Scientific Publications Continue ReadingALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study
